Regulatory Gap Analysis for Drug Development Programs
Identify risks before they delay development
Get a practical assessment of regulatory, CMC, clinical pharmacology, and development readiness so you can move toward your next milestone with a clearer plan.
Uniphar helps biotech and pharma teams identify the regulatory, scientific, and operational gaps that can slow progress toward key development milestones. Whether you are preparing for a Pre-IND meeting, an IND submission, or a broader regulatory strategy reset, a structured gap analysis helps clarify what is missing, what needs to be strengthened, and what should happen next.
Identify gaps before they delay your next milestone
A regulatory gap analysis gives your team a practical view of readiness across the areas that matter most. Instead of broad recommendations, Uniphar focuses on the issues most likely to affect timelines, agency interactions, and execution.
What a Regulatory Gap Analysis Can Help Uncover
- Gaps in overall regulatory strategy
- Missing or underdeveloped submission components
- Misalignment across regulatory, CMC, clinical pharmacology, and data
- Risks that could affect meeting readiness or filing timelines
- Areas where internal teams need added depth or faster execution
When a regulatory gap analysis makes sense
- Preparing for a Pre-IND meeting
- Planning an IND submission
- Reassessing program strategy after new data or investor feedback
- Trying to understand why timelines are slipping
- Working with limited internal development bandwidth
Preparing for an upcoming FDA Meeting?
Download the free FDA Meeting Mastery: A Guide to Go from Request to Regulatory Win to reduce uncertainty and strengthen every FDA interaction.
What You Receive
Uniphar’s gap analysis is designed to help you move from uncertainty to action.
Typical Regulatory Gap Analysis Outputs
- Assessment of current-state readiness
- Prioritized risks and gaps
- Recommended next steps by function
- Input on likely near-term regulatory priorities
- A clearer path toward Pre-IND, IND, or broader development planning
Common Pitfalls We Help You Avoid
- Overbuilding “nice-to-have” workstreams while critical path items lag
- Misalignment between CMC plans and early clinical needs
- Data plans that don’t support clean downstream analysis and timelines
Why Uniphar
Uniphar brings cross-functional development expertise into the review process, with experienced leaders across regulatory, clinical pharmacology, CMC, data, and delivery.
Experience That Supports Better Decisions
Since 2002, Uniphar’s development division has supported more than 200 organizations across major therapeutic areas and development settings, with a 20+ year track record, 50+ integrated programs advanced, and $3.0B+ in asset value creation.
A Track Record of Value Creation
Uniphar (formerly RRD Biopharma Development) had an eleven-year development partnership with Nitto on multiple assets utilizing its novel siRNA technology to develop antifibrotic medicines targeting advanced hepatic fibrosis due to non-alcoholic steatohepatitis (NASH), and Idiopathic Pulmonary Fibrosis (IPF). Uniphar supported advancement of Nitto’s assets through Phase 2 clinical trials. The partnership enabled Nitto to enter into an exclusive worldwide licensing agreement with Bristol Myers Squibb which included a $100 million upfront payment and subsequent development milestones and royalties.
Regulatory Gap Analysis FAQs
We tailor the assessment to your next milestone—Pre‑IND/IND planning, FDA interactions, or broader development decisions.
No— Uniphar facilitates regulatory submissions beyond the FDA, covering ex-US regulatory health authorities, including the European Medicines Agency (EMA) and other international health authorities, to support global development programs.
Yes—CMC process and analytical gap analyses are available as focused engagements.
Many teams use the roadmap to prepare for a Pre‑IND meeting, IND readiness work, or targeted remediation.
Complimentary 30-minute consultation with a senior regulatory program leader (the same experts who do the work).
Meet directly with a senior Uniphar development leader to discuss where your program may have avoidable gaps, which issues are most likely to affect timing or readiness, and what next steps would create the most value.